Terminated PHASE3 NCT00123903

COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria

A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria

Sponsor: GlaxoSmithKline

Conditions Heart Failure, Congestive and Microalbuminuria

Interventions carvedilol MR lisinopril metoprolol xl

Updated 6 times since 2017 Last updated: Jan 16, 2017 Started: Jul 31, 2005 Primary completion: May 31, 2006 Completion: May 31, 2006

This PHASE3 trial investigates Heart Failure, Congestive and Microalbuminuria and is currently terminated or withdrawn. GlaxoSmithKline leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Avon, United States , Ayer, United States , Bay Roberts, Canada , Beaumont, United States , Beaver, United States , Birmingham, United States , Bonaventure, Canada , Brampton, Canada , Buffalo, United States , Burke, United States and 74 more locations